Want to see SE:NICA full AI Analyst Report?
NICA Stock Chart & Stats
kr0.74
kr0.03(1.43%)
At close: 4:00 PM EST
kr0.74
kr0.03(1.43%)
Day’s Range― - ―
52-Week Rangekr0.33 - kr2.25
Previous CloseN/A
Volume105.00
Average Volume (3M)111.94K
Market Cap
kr163.07M
Enterprise Valuekr133.48M
Total Cash (Recent Filing)kr39.25M
Total Debt (Recent Filing)kr119.07M
Price to Earnings (P/E)1.8
Beta1.40
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.27
Shares Outstanding328,769,840
10 Day Avg. Volume89,035
30 Day Avg. Volume111,941
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)3.04
Price to Sales (P/S)3.26
P/FCF Ratio-1.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.1
Revenue Forecast (FY)kr141.40M
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthTTM revenue growth of +50.7% indicates durable commercial traction for Nanologica’s silica chromatographic products in pharmaceutical separations. Sustained top-line expansion improves the company's ability to achieve operating leverage, scale manufacturing and offset fixed R&D costs if cost discipline follows.
Large Capital Base / Positive EquityReported total assets of ~262.3M and positive equity provide a meaningful capital base to fund R&D, manufacturing scale-up and customer programs without immediate dependence on operating cash flow. This balance-sheet capacity gives runway to commercialize and validate product-market fit over the medium term.
Positive Return On Equity (TTM)A positive TTM return on equity, despite operating losses, signals that invested capital has produced accounting returns; this can reflect improving capital efficiency or successful financing/investment outcomes. It provides a structural foothold for management to convert accounting gains into sustainable operating profitability if execution continues.
Bears Say
Negative Operating & Free Cash FlowTTM operating and free cash flow deficits (~-26.9M and -27.9M) indicate persistent cash burn that forces reliance on external financing. This constrains investment flexibility, raises dilution and refinancing risk, and limits the company's ability to self-fund scaling or absorb cyclical shocks until cash generation turns positive.
Negative Gross And Operating MarginsDeeply negative gross and operating profits show the core business has not yet achieved sustainable unit economics. Structural margin deficits imply the company needs improved pricing power, cost reduction, or higher-yield product mix to reach operating profitability and avoid continued dependence on external capital.
Rising Leverage (debt-to-equity ~1.22)Debt-to-equity of ~1.22 represents materially higher leverage while operations remain loss-making. Elevated leverage increases fixed obligations and interest vulnerability, reduces strategic flexibility, and heightens refinancing risk if operating cash flows fail to improve over the medium term.
Nanologica AB News
NICA FAQ
What was Nanologica AB’s price range in the past 12 months?
Nanologica AB lowest stock price was kr0.33 and its highest was kr2.25 in the past 12 months.
What is Nanologica AB’s market cap?
Nanologica AB’s market cap is kr163.07M.
When is Nanologica AB’s upcoming earnings report date?
Nanologica AB’s upcoming earnings report date is Aug 27, 2026 which is in 52 days.
How were Nanologica AB’s earnings last quarter?
Nanologica AB released its earnings results on May 20, 2026. The company reported kr0.719 earnings per share for the quarter, beating the consensus estimate of N/A by kr0.719.
Is Nanologica AB overvalued?
According to Wall Street analysts Nanologica AB’s price is currently Overvalued.
Does Nanologica AB pay dividends?
Nanologica AB does not currently pay dividends.
What is Nanologica AB’s EPS estimate?
Nanologica AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Nanologica AB have?
Nanologica AB has 328,769,840 shares outstanding.
What happened to Nanologica AB’s price movement after its last earnings report?
Nanologica AB reported an EPS of kr0.719 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 32.383%.
Which hedge fund is a major shareholder of Nanologica AB?
Currently, no hedge funds are holding shares in SE:NICA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Nanologica AB
Nanologica AB (publ), a nanotechnology company, develops, manufactures, and sells nanoporous silica particles for life science industry in China, India, the United State of America, and internationally. It offers NLAB Saga, a new generation silica for preparative chromatography; and SVEA, a pre-packaged columns for analytical chromatography; and high-performance liquid chromatography, a separation method based on different substances in a solution passing through a column at different paces. The company provides products for the analysis and purification of substances, with a focus on peptides drugs for the treatment of diabetes and obesity. Nanologica AB (publ) was incorporated in 2004 and is headquartered in Södertälje, Sweden.
Technical Analysis
Alzinova AB
―
Biosergen AB
―
Biovica International AB Class B
―
NextCell Pharma AB
―
Spago Nanomedical AB
―